Kathrin M. Bernt, MD Kathrin M. Bernt, MD, is a Pediatric Oncologist in the Cancer Center's Leukemia and Lymphoma Program at Children's Hospital of Philadelphia. Locations: Main Campus Appointments and Referrals: 1-800-TRY-CHOP (1-800-879-2467) Education and Training Medical SchoolMD - Humboldt University Berlin, Germany InternshipPediatrics - Seattle Children's Hospital - University of Washington, Seattle, WA ResidencyPediatrics - Texas Children's Hospital - Baylor College of Medicine, Houston, TX Pediatrics - Charite - Humboldt University Berlin, Germany FellowshipPediatric Hematology/Oncology - DFCI/Boston Children's Hospital, Boston, MA Titles and Academic Titles Attending PhysicianAssistant Professor, Perelman School of Medicine, University of Pennsylvania Conditions Treated Acute Lymphoblastic Leukemia (ALL) Acute Myelogenous Leukemia (AML) Hodgkin LymphomaNon-Hodgkin Lymphoma in ChildrenRelapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Departments and Services Cancer CenterLeukemia and Lymphoma Program Publications Papers2016 Haladyna JN, Pastuer T, Riedel SS, Perraud AL, Bernt KM. Transient Potential Receptor Melastatin-2 (TRPM2) Does Not Influence Murine MLL-AF9 Driven AML Leukemogenesis or in Vitro Response to Chemotherapy. Exp Hematol. 2016 Mar 23, PMID: 27033163 Riedel SS, Haladyna JN, Bezzant M, Stevens B, Pollyea DA, Sinha AU, Armstrong SA, Wei Q, Pollock RM, Daigle SR, Jordan CT, Ernst P, Neff T* and Bernt KM*. The Histone Methyltransferases MLL and DOT1L cooperate with Meningioma-1 to induce AML. J Clin Invest. 2016 Feb 29. PIMD 26927674 Danis E, Yamauchi T, Echanique K, Zhang X, Haladyna J, Riedel SS, Zhu N, Xie H, Orkin SH, Armstrong SA, Bernt KM* and Neff T*. Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T-Cell Precursor Acute Lymphoblastic Leukemia. Cell Reports 2016 Mar1; 14(8): 19953-65. PIMD 26904942 2015 Danis E, Yamauchi T, Echanique K, Haladyna J, Kalkur R, Riedel S, Zhu N, Xie H, Bernt KM, Orkin SH, Armstrong SA, Neff T. Inactivation of Eed Impedes MLL-AF9 Mediated Leukemogenesis Through Cdkn2a-Dependent and Cdkn2a-Independent Mechanisms in a Murine Model. Exp Hematol. 2015 Nov;43(11):930- 935. PMID:26118502 Chen CW, Koche RP, Sinha AU, Deshpande AJ, Zhu N, Eng R, Doench JG, Xu H, Chu SH, Qi J, Wang X, Delaney C, Bernt KM, Root DE, Hahn WC, Bradner JE, Armstrong SA. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat Med. 2015 Apr;21(4):335-43. PMID 25822366 Deshpande AJ, Deshpande AA, Sinha AU, Chen L, Chang J, Zhu N, Koche R, Dzekieva L, Ibanez G, Dias S, Banka D, Krivtsov A, Luo M, Roeder R, Bradner JE, Bernt KM, Armstrong SA. Hox gene expression is controlled by AF10-mediated conversion of H3K79me1 to H3K79me2 in diverse AML subtypes. Cancer Cell 2014 Dec 8;26(6):896-908. PMID: 25464900 BooksChapters 2009 Bernt KM, Feigin DR. Interaction of Infection and Nutrition. In: Feigin, Cherry, Demmler, Kaplan: Textbook of Pediatric Infectious Diseases, 5th edition (Feb 2009). 1995 Reutter W, Baum O, Loester K, Fan H, Bork JP, Bernt K, Hanski C, Tauber R. Functional Aspects of the 3 extracellular domains od dipeptidyl peptidase IV (CD26): characterization of glycosylation events, of the collagen binding site and of endopeptidase activity. In: Mol. Biol. Intelligence Units. DPP IV / CD26 in Metabolism and Immune Response. Ed. B. Fleischer, Springer, 1995, pp 55-78. Posters and PresentationsPoster Presentations 2016 Wolfe Schneider, K., Wei, Qi, Kuldanek, S., Bernt, KM. Case example involving germline genetic counseling needs for 47,XXX, familial leukemia, and Noonan syndrome following somatic genetic testing. American Society of Pediatric Hematology Oncology (ASPHO) annual meeting, Minneapolis, MN, 2016 – poster presentation. 2015 Simone Riedel, Jessica Haladyna, Matthew Bezzant, Brett Stevens, Daniel A. Pollyea, Amit U. Sinha, Scott Armstong, Qi Wei, Craig T. Jordan, Patricia Ernst, Tobias Neff and Kathrin M. Bernt. Meningeoma-1 cooperates with MLL and DOT1L to induce leukemia. American Society of Hematology (ASH) annual meeting, Orlando, FL, 2015 – poster presentation. Kathrin M. Bernt. Epigenetics Directing Therapy in Acute Lymphocytic Leukemia: Emerging Roles and New Therapies. American Society of Hematology (ASH) annual meeting, Orlando, FL, 2015 – invited oral presentation. 2014 Simone Riedel, Jessica Haladyna, Matthew Bezzant, Brett Stevens, Daniel A. Pollyea, Craig T. Jordan, Qi Wei, Tobias Neff and Kathrin M. Bernt. Targeting Meningeoma-1 driven AML through epigenetic modulation of the cell of origin. American Society of Hematology (ASH) annual meeting, San Francisco, CA, 2014 – oral presentation. Jessica N. Haladyna, Taylor L. Yamauchi, Tobias Neff and Kathrin M. Bernt. MDR1 Mediated Drug Resistance to a Histone Methyltansferase Inhibitor (KMT). American Society of Hematology (ASH) annual meeting, San Francisco, CA, 2014 – poster presentation. Taylor Yamauchi, BA, Kristen Echanique, BS, Jessica Haladyna, BA, Huafeng Xie, Ph.D., Nan Zhu, Ph.D., Simone Riedel, Ph.D., Kathrin M Bernt, MD1, Stuart H. Orkin, MD, Scott A. Armstrong, MD, PhD and Tobias Neff. Context Dependent Role of Polycomb Repressive Complex 2 in Acute Leukemia. American Society of Hematology (ASH) annual meeting, San Francisco, CA, 2014 – oral presentation. Lectures by Invitation 2015 Bernt K. Epigenetics directing therapy in acute lymphocytic leukemia: emerging roles and new therapies. Presented at: ASH Annual meeting: Scientific Program; 2015 Dec 5; Orlando, FL. Bernt K. How to start a successful laboratory. Presented at: Children’s Hospital Boston/Dana Farber Cancer Institute/Harvard Medical School; 2015 Nov 20; Boston, MA. Bernt K. Meningioma-1 cooperates with MLL1 and DOT1L to induce leukemia. Presented at: AACR Advances in Pediatric Oncology Meeting; 2015 Nov 10; Fort Lauderdale, FL. Bernt K. Meningioma-1 driven AML depends on the histone methyltransferase DOT1L. Presented at: Doris Duke Clinical Scientist Meeting; 2015 Apr 23; Chicago, IL. Bernt K. Targeting Meningeoma-1 driven AML through epigenetic modulation of the cell of origin. Presented at: Keystone Meeting in Hematopoiesis; 2015 Feb 23; Keystone, CO. 2014 Bernt K. DOT1L inhibition in leukemias with and without MLL-rearrangement. Presented at: COG (Children’s Oncology Group) Fall Meeting, ALL Biology Session; 2014 Sep 17; Dallas, TX. Bernt K. Histone profiling in cancer using ChIP-Seq and Mass Spec (together with Ken Figueroa: DNA-methylation profiling, Lucy Godley: DNA hydroxymethylation profiling). Presented at: AACR annual meeting methods workshop; 2014 Apr 5; San Diego, CA. Awards and Honors 2015, AACR Advances in Pediatric Cancers Meeting – early career presenter 2013, ASCI Council's 2013 Young Physician-Scientist Awards, Annual Meeting of the American Society of Clinical Investigation, Chicago, IL 2010, SIOP Award in Translational Research, Annual Meeting of the Société International d’Oncologie Pediatrique, Boston, MA 2002, Excellency in Research Award, Annual Meeting of the American Society of Gene Therapy, Boston 2002, Travel Award, Annual Meeting of the American Society of Gene Therapy, Boston, MA 2000, Travel Award, Annual Meeting of the American Society of Hematology, San Francisco, CA Editorial and Academic Positions Editorial Board 2015, Associate Editor Frontiers in Oncology and Pediatrics Ad Hoc Reviewer 2015-present, Nature Communications 2015-present, Blood 2015-present, Pediatric Blood and Cancer 2015-present, Oncotarget 2015-present, Journal of Genetic Counseling 2015-present, International Journal of Molecular Sciences 2014-present, Journal of Clinical Investigation 2013-present, Cancer Research 2013-present, Leukemia Research 2013-present, Molecular Cancer Therapeutics Leadership and Memberships 2016, American Society of Cancer Research (AACR), Full Member Patient Experience Ratings About the Patient Experience Rating System The Patient Experience Rating is an average of all responses to the care provider related questions shown above from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question. Responses are measured on a scale of 1 to 5 with 5 being the best score. We are committed to true transparency. However, to ensure the comments are fair and correctly attributed, we review each one before posting to the website. We exclude entire comments that disclose patient's protected health information, are off-topic, or include other confidential or inappropriate content. Comments will appear on provider bios only if providers have a minimum number of comments. Comments are shared internally for education purposes to ensure that we are doing our very best for the patients and families for whom we are privileged to care. The comments are submitted by patients and families and reflect their views and opinions. The comments are not endorsed by and do not reflect the views of Children’s Hospital of Philadelphia.